Delivery Order SPE2DB24D2205-SPE2DB25FECGV
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order for YONSA 125 MG tablets (120-count) valued at $4,542.74 by the Medical Supply Chain, a defense-focused federal agency, with an award date of September 3, 2025 and ultimate completion date of September 24, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. The place of performance is AmerisourceBergen's corporate office located in Conshohocken,...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Yonsa 125 mg tablets (120-count units) valued at $4,542.74. This firm fixed-price, competitively awarded contract has an ultimate completion date of September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under a larger contract vehicle,...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract worth $13,172.88 to AmerisourceBergen Drug Corp, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of 4563956683 - YONSA 125 MG TABLET 120S, a specialty pharmaceutical product, with a period of performance through April 3, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) worth up to...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency for YONSA 125 mg tablets (120 count) valued at $2,271.36. This firm fixed-price, competitively awarded contract (no set-aside used) represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, designated SPE2DX and valued at approximately $1 billion through December 2026. The delivery order is...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division. The $2,195.48 firm-fixed-price contract is for the delivery of 4,565,965,358 units of YONSA 125 MG Tablet 120S, a pharmaceutical product. The contract has an ultimate completion date of October 21, 2024. AmerisourceBergen is a major pharmaceutical distributor that supplies a wide range of medical products and drugs to various government agencies and healthcare...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order worth $2,195.48 to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 through December 2025, which serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of...
- The Defense Logistics Agency awarded a $2,271.36 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Yonsa 125 mg tablets (120 count). The contract is a firm fixed-price delivery order with a completion date of September 17, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The $4,390.96 contract is for the supply of 4563557510 YONSA 125 MG TABLET 120S, a specialty pharmaceutical product. The contract has a completion date of February 27, 2024 and was awarded on February 5, 2024. This delivery order is issued under Amerisourcebergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $9,085.44 to AmerisourceBergen Drug Corp for 120 tablets of Yonsa 125 mg, a pharmaceutical product supporting military healthcare needs. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $4,542.74 to AmerisourceBergen Drug Corp for 120 tablets of Yonsa 125 mg, a pharmaceutical product. The contract, awarded on August 12, 2025, carries a firm fixed-price structure with an ultimate completion date of September 3, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FECGVDelivery Order
AmerisourceBergen Drug Corp received a $2,271.36 delivery order from the Defense Logistics Agency (DLA) on May 13, 2025, for the supply of YONSA 125 mg tablets (120-count units). The contract is classified as a firm fixed price delivery order with an ultimate completion date of June 4, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award represents a non-set-aside procurement awarded through competitive means, consistent with AmerisourceBergen's extensive track record of federal medical supply contracting. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime contract vehicle designated SPE2DX and extending through December 2026. As a leading pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to support military healthcare systems and other government agencies. The company's federal contracting demonstrates its capability to fulfill diverse pharmaceutical requirements ranging from specialty medications to generic drugs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 5/13/25 |